Aspen’s subsidiary in Japan was officially opened in May 2015. Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The Japanese pharmaceutical sector declined 4,5% and was valued at USD80 billion as at 30 June 2017.
- The sector was negatively impacted by a 20,6% decline in off-patent drugs due to price revisions and increased generic penetration.
Source: June 2017 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2017||2016 (CER)*||% change|
|High Potency & Cytotoxics||0,4||0,5||(16)|
|Other Commercial Pharmaceutical Brands||0,2||0,1||67|
* Constant exchange rate: FY16 restated at FY17 average exchange rates.
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.